The EU Commission starts a market test on the proposed commitments offered by a pharmaceutical company to address the Commission’s concerns over excessive pricing on a range of off-patent cancer medicines (Aspen)

Today, the European Commission (the Commission) started a market test inviting comments from interested parties on commitments offered by Aspen Pharmacare Holdings (Aspen) to address the Commission's concerns over excessive pricing for a range of off-patent cancer medicines (see, attached Commission press release). Broadly, Aspen’s proposed commitments are the following: a) Applying a price